(Total Views: 741)
Posted On: 02/14/2017 7:24:37 AM
Post# of 44
$BLFS. breakout candle held: $2.10
Above upper bollie
Nasdaq CM
Ultra Low Float (below)
Website
2/14/17
$BLFS an equity partner in SAVSU Technologies
SAVSU Technologies Provides Performance Update
on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics
Phase 3 Glioblastoma Cell Therapy Clinical Trial
Website
BioLife Solutions Announces 2016 Revenue Growth of 28 %
2017 Guidance Provided 1/12/17
100% x 100% Strong Buy
10 K/A 12/9/2016
Last 10 trades
Stock technical analysis
Shares Outstanding 12.88M
Float 6.3M
% Held by Insiders 51.44%
% Held by Institutions 3.40%
Shares Short 199.37k
Short Ratio 5.8
Short % of Float 6.04%
Shares Short (prior month) 208.77k
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
Above upper bollie
Nasdaq CM
Ultra Low Float (below)
Website
2/14/17
$BLFS an equity partner in SAVSU Technologies
SAVSU Technologies Provides Performance Update
on evo® Cold Chain 2.0™ System in ImmunoCellular Therapeutics
Phase 3 Glioblastoma Cell Therapy Clinical Trial
Website
BioLife Solutions Announces 2016 Revenue Growth of 28 %
2017 Guidance Provided 1/12/17
100% x 100% Strong Buy
10 K/A 12/9/2016
Last 10 trades
Stock technical analysis
Shares Outstanding 12.88M
Float 6.3M
% Held by Insiders 51.44%
% Held by Institutions 3.40%
Shares Short 199.37k
Short Ratio 5.8
Short % of Float 6.04%
Shares Short (prior month) 208.77k
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
(0)
(0)
